Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- TSH
研究概览
简要总结
Differentiated thyroid cancer is the most common neoplasm of endocrine system. After surgery and radioiodine treatment, thyroid stimulating hormone (TSH) suppression is the main goal which is achieved with levothyroxine treatment. Levothyroxine causes increased thyroid hormones which can have negative impact on bone and cardiovascular system. Anecdotal reports have shown that metformin can induce TSH suppression without change in T3 and T4 concentration. The purpose of this study was to prescribe metformin as additional drug to levothyroxin in order to decrease levothyroxine dosage.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 80 Years(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •papillary or follicular thyroid cancer
- •stage 1 or 2 according to TNM system version 6
- •surgery and radioiodine treatment
- •levothyroxine suppression treatment
排除标准
- •cardiopulmonary failure
- •liver failure
- •renal failure
- •pregnancy
- •drugs (colestyramin, sucralfate, phenobarbital, phenytoin, carbamazepin, rifampin, amiodarone, chloroquin, androgens, sertraline, frusemide, heparin)
研究组 & 干预措施
metformin
patients who receive metformin in addition to levothyroxine
干预措施: Metformin (Drug)
levothyroxine
patients who receive only levothyroxine
干预措施: Metformin (Drug)
结局指标
主要结局
TSH
时间窗: 3 months
次要结局
- freeT3,freeT4(3months)
